{"id":19218,"date":"2026-06-10T21:30:00","date_gmt":"2026-06-10T19:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=06dca6744010c6fa69925bd047537ad3"},"modified":"2026-06-10T21:30:00","modified_gmt":"2026-06-10T19:30:00","slug":"snke-and-precision-neuromed-partner-to-accelerate-learning-cycles-in-precision-brain-therapies","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=19218","title":{"rendered":"Snke and Precision NeuroMed Partner to Accelerate Learning Cycles in Precision Brain Therapies"},"content":{"rendered":"<p class=\"bwalignc\">\n<i>Collaboration will enable better decisions, higher treatment quality, and scalable clinical impact for better outcomes for patients<\/i><\/p><p>MUNICH & REDWOOD CITY, Calif.--(BUSINESS WIRE)--<a href=\"https:\/\/twitter.com\/hashtag\/AI?src=hash\" >#AI<\/a>--<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.snke.com%2F&amp;esheet=54550963&amp;newsitemid=20260610088596&amp;lan=en-US&amp;anchor=Snke&amp;index=1&amp;md5=571449b2f15aaf4d2e6a564ea6496a20\" rel=\"nofollow\" shape=\"rect\">Snke<\/a>, a pioneering health tech company, and <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fprecisionneuromed.com%2F&amp;esheet=54550963&amp;newsitemid=20260610088596&amp;lan=en-US&amp;anchor=Precision+NeuroMed&amp;index=2&amp;md5=78eebcc80d56b2a3a6999410375d891b\" rel=\"nofollow\" shape=\"rect\">Precision NeuroMed<\/a> (PNM), a clinical-stage biotechnology company advancing precision therapeutics for central nervous system (CNS) diseases, announced a partnership to streamline and scale precision drug delivery to the brain through digital workflow orchestration.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260610088596\/en\/2828118\/5\/PNM_transparent_logo_no_sub.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260610088596\/en\/2828118\/22\/PNM_transparent_logo_no_sub.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260610088596\/en\/2828118\/5\/PNM_transparent_logo_no_sub.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260610088596\/en\/2828118\/21\/PNM_transparent_logo_no_sub.jpg\" \/><\/a><p>\nAs part of the collaboration, PNM will leverage the clinical workflow and collaboration engine, Snke Cockpits, to manage complex treatment planning workflows in the cloud. Snke Cockpits enable structured case coordination, transparent collaboration, and secure data exchange\u2014connecting stakeholders across institutions in a seamless, digitally integrated environment.<\/p><p>\nIn addition, Snke and PNM agreed to establish a data-driven clinical registry designed to systematically capture imaging, planning, procedure, and outcome data for targeted drug delivery treatments. By combining workflow management with structured real-world data collection, the partnership aims to accelerate learning cycles in precision drug delivery and to create a scalable foundation for future therapies on the central nervous system (CNS).<\/p><p>\n\u201cPrecision therapies require precision workflows,\u201d said Stefan Vilsmeier, Founder and CEO of Snke. \u201cWith Snke Cockpits, we are building the digital backbone that connects clinicians, experts, and data\u2014always with the patient at the center.\u201d<\/p><p>\n\u201cDelivering advanced CNS therapies is not just about biology\u2014it\u2019s about coordination, data and continuous improvement,\u201d said Sandeep Kunwar, MD, Founder and CEO of PNM. \u201cPartnering with Snke allows us to operationalize excellence and build a high-quality data foundation for the future of precision brain therapies.\u201d<\/p><p>\nThe collaboration reflects a shared ambition to combine therapeutic innovation with modern digital infrastructure\u2014enabling better decisions, higher treatment quality, and scalable clinical impact.<\/p><p>\n<b>About Snke<\/b><\/p><p>\nHeadquartered in Munich, Snke is transforming healthtech with scalable, data-driven innovation powered by AI and big data. We\u2019re more than 350 experts specializing in healthcare IT, advanced visualization and simulation, data science and machine learning. By delivering a trusted orchestration layer, Snke empowers healthcare providers, clinical societies, patients and other healthtech companies to utilize cutting-edge solutions for improving treatments and enhancing patient outcomes. Beyond our Munich headquarters, we have core teams in Chicago, Heidelberg and Tel Aviv. Snke fosters global collaboration to create technologies that are smart, enabling and holistic\u2014helping healthtech to scale up data innovation.<\/p><p>\nFor more information, visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.snke.com%2Fstartpage&amp;esheet=54550963&amp;newsitemid=20260610088596&amp;lan=en-US&amp;anchor=Snke&amp;index=3&amp;md5=fdbfd8452ec2a57aaae9e12cb1d2cbdc\" rel=\"nofollow\" shape=\"rect\">Snke<\/a> or follow us on <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsnke%2F&amp;esheet=54550963&amp;newsitemid=20260610088596&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=37303eb9c8daf0561f10ea9e53c671a7\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a>, <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fsnkecorporate&amp;esheet=54550963&amp;newsitemid=20260610088596&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=e021311d7068086fa154e8ae49a76eee\" rel=\"nofollow\" shape=\"rect\">Facebook<\/a> and <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fsnkecorporate%2F&amp;esheet=54550963&amp;newsitemid=20260610088596&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=b0ef592d74b0ac66331c6eb8f9adcc21\" rel=\"nofollow\" shape=\"rect\">Instagram<\/a><\/p><p>\n<strong>About Precision NeuroMed<\/strong><\/p><p>\nHeadquartered in Redwood City, CA, Precision NeuroMed (PNM) is a clinical-stage biotechnology company pioneering next-generation therapies to cure neurological diseases. Unlike traditional approaches that focus on managing symptoms, PNM is developing disease-modifying treatments enabled by advanced drug delivery platforms engineered specifically for the brain. Our mission is to combine best-in-class biological drugs with innovative delivery strategies to achieve meaningful, lasting improvements for patients suffering from devastating neurological conditions.<\/p><p>\nFor more information, please visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fprecisionneuromed.com%2F&amp;esheet=54550963&amp;newsitemid=20260610088596&amp;lan=en-US&amp;anchor=precisionneuromed.com&amp;index=7&amp;md5=c4dbe9a384104da096d1b6ec5691ce7d\" rel=\"nofollow\" shape=\"rect\">precisionneuromed.com<\/a> or <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fprecisionneuromed%2F&amp;esheet=54550963&amp;newsitemid=20260610088596&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=b3c20cadee4d4b28d25e851e7bd7acae\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nJennifer Baskerville\n<br\/><a  href=\"mailto:Jennifer@BaskervillePR.com\" rel=\"nofollow\" shape=\"rect\">Jennifer@BaskervillePR.com<\/a><br\/>703-967-2590<\/p>","protected":false},"excerpt":{"rendered":"<p>Collaboration will enable better decisions, higher treatment quality, and scalable clinical impact for better outcomes for patientsMUNICH &amp; REDWOOD CITY, Calif.&#8211;(BUSINESS WIRE)&#8211;#AI&#8211;Snke, a pioneering health tech company, and Precision NeuroMed (PNM&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-19218","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19218"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19218\/revisions"}],"predecessor-version":[{"id":19219,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19218\/revisions\/19219"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}